- Joined
- 19 August 2021
- Posts
- 249
- Reactions
- 736
The company is pleased to report we have reached breakeven/profit, excluding non-cash expenses.
Steadily moving down and now through the $1.7 mark. with a 1-3 buy sell ratio.I’ve been watching PNV recently because it has fallen to a point that could be a turning point. ........
There is a strong level of resistance at $2.04 that price recently bounced off. If price moves back down to break this level, further falls could be expected. The next stop down (and one that has some analysis that suggests it is the bottom) is $1.75. This level is a 161.8% Fibonacci retracement of what I see as possibly Wave B (Elliott Wave Theory).
......
There are suggestions that the $2.04 low will hold in that the blue dashed line is a line of support that has held under price for 3 years. The probability that this support will be broken isn’t good (except for those who bought on the bounce). Interestingly, if price did fall through $2.04 with any volume then that would give a target of $1.76 for a short term fall.
My pick this year as Covid will be over, heaps of operations required, people back in hospital, new CEO, expect 100% growth or I will be very disappointed. Out of favour. In favour last year (+ issues with the new hernia treatment sticking) which is why I didn't pick it.Hope fully nearing the end of a down trend.
Would like to think $1.4 is support.
But is a long term turnaround story.
"While US sales are very encouraging, there is more to achieve as we still have new sales staff being onboarded and more staff to be employed. In addition, we are retraining existing staff to follow surgeon leads using the product in new indications. While the US is the engine room of our growth in the immediate future, there are many opportunities in the rest of the world where we are just starting out."
"I am very excited about the potential of PolyNovo’s technology and its ability to impact patient outcomes across world. In my 30-plus years in healthcare, I have never seen such an impressive technology combined with very attractive financial metrics,” he said in a statement to the ASX.
“PolyNovo has all the elements needed to build a truly global and very large Australian life sciences multinational along the lines of a number of other Australian success stories. It was this potential that brought me out of retirement.”
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?